MarketInOut Stock Screener Log In | Sign Up
 

CervoMed Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 09/18/2026
CervoMed Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization36.89 mln
Float12.23 mln
Earnings Date11/16/2026

Piotroski F-Score

3 / 9
Below average

1-Year Forecast

15.40
Transformational upside

Relative Strength

28 / 100
Underperforming

Pre-Tax Margin

-9,409%
Severely loss-making

ROE

-136
Deeply negative

ROA

-114
Deeply negative

Business Description

CervoMed is a Boston-based biotech company focused on treating brain diseases that worsen with age. Its lead drug, neflamapimod, is a pill that enters the brain and blocks a protein linked to nerve cell damage, with the goal of preserving brain function and slowing disease progression. The company is currently testing neflamapimod in patients with several serious conditions, including dementia with Lewy bodies, a progressive speech disorder, and ALS.

Key Fundamentals

EPS-3.21
ROE-136
RPS0.04
ROIC-3,081
ROA-114
EBITDA, mln-31.17
EV / EBITDA-0.46
EV / EBIT-0.46
Revenue, mln0.33
EV / Revenue36.31

Quote Details

Last 2.43
Change -0.12 (-4.71%)
Open 2.53
Volume 179,107
Turnover 435,230
Average Volume 183,170

Financial Ratios

Pre-Tax Profit Margin-9,409
Leverage Ratio1.13
Current Ratio8.57
Price / Book1.53
Price / Tangible Book1.53
Price / Sales70.04

Financial Strength

Piotroski F-Score 3 / 9
1-Year Target Price15.40
Short Ratio3.90
Short % of Float10.88

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -5.45% 13 / 100   
1 Month -10.33% 20 / 100   
2 Months -0.41% 47 / 100   
6 Months -42.55% 10 / 100   
1 Year -68.81% 10 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us